HighTower Advisors
RPRX icon

HighTower Advisors’s Royalty Pharma RPRX Stock Holding History

HighTower Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,000
Closed -$779 – 3938
2024
Q2 		$779 Hold
5,000
– – ﹤0.01% 3574
2024
Q1 		$2.63K Buy
+5,000
New +$147K ﹤0.01% 3470

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HighTower Advisors's RPRX Position: Q1 2026 in Review

HighTower Advisors increased its Royalty Pharma (RPRX) stake by 4.2% in Q1 2026, buying an estimated $517K and bringing the position to 292,921 shares worth $14.1M. The position accounts for 0.01% of the portfolio, ranked #741.

HighTower Advisors first reported a position in RPRX in Q2 2021 and has held it in 20 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • HighTower Advisors held 292,921 shares of Royalty Pharma worth $14.1M as of Q1 2026.
  • HighTower Advisors bought 11,799 Royalty Pharma shares in Q1 2026, an estimated $517K.
  • Royalty Pharma made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #741 holding.
  • HighTower Advisors first reported a position in Royalty Pharma in Q2 2021 and has held it in 20 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.